Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of “Buy” from Brokerages

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have earned an average recommendation of “Buy” from the eight brokerages that are presently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $12.6250.

Separately, Wedbush reaffirmed an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, May 5th.

Perspective Therapeutics Stock Down 0.7%

NYSEAMERICAN:CATX opened at $2.95 on Friday. Perspective Therapeutics has a 1-year low of $1.96 and a 1-year high of $6.16. The company has a 50-day moving average of $3.33 and a 200 day moving average of $3.90.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.16 million. As a group, analysts expect that Perspective Therapeutics will post -1.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of large investors have recently bought and sold shares of the business. UBS Group AG lifted its stake in shares of Perspective Therapeutics by 44.5% during the 4th quarter. UBS Group AG now owns 926,331 shares of the company’s stock worth $2,547,000 after purchasing an additional 285,188 shares during the last quarter. Avidity Partners Management LP grew its stake in Perspective Therapeutics by 7.2% in the fourth quarter. Avidity Partners Management LP now owns 3,210,733 shares of the company’s stock valued at $8,830,000 after purchasing an additional 216,700 shares during the last quarter. AXQ Capital LP grew its stake in Perspective Therapeutics by 24.2% in the fourth quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after purchasing an additional 2,481 shares during the last quarter. R Squared Ltd bought a new position in Perspective Therapeutics in the fourth quarter worth about $44,000. Finally, Octagon Capital Advisors LP bought a new position in Perspective Therapeutics in the first quarter worth about $3,301,000. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.